Aspen Neuroscience Files S-1 for Nasdaq IPO
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Aspen Neuroscience filed an S-1 registration statement with the SEC to list on Nasdaq. The company is focused on patient-derived cell therapy for Parkinson's disease. Five underwriters, led by Leerink Partners, are handling the offering. The filing did not include a price range or share count, so the deal size is currently undetermined.
From 247wallst.com
Why it matters
The IPO offers a potential public entry point into the patient-derived cell therapy field, which is described as narrow and capital-intensive. The offering marks Aspen Neuroscience's transition from a privately funded biotech company to a registered offering.
From 247wallst.com
Who's involved
- NasdaqThe stock exchange where Aspen Neuroscience is pursuing its IPO.
- SECThe regulatory body overseeing the S-1 filing.
- Leerink partnersLeading the five-bank syndicate underwriting the IPO.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Leerink partnersSpeculative
Leerink Partners could see increased revenue from underwriting fees if the IPO is successful.
Keep exploring
The entities involved
Related events
- Pine Tree Acquisition Corp. filed its S-1 registration statement with the SEC and priced IPO units for listing on Nasdaq.
- NeuroOne Medical Technologies announced its stock listing on the Nasdaq exchange.
- Amaero Inc. filed an S-1 registration statement with the SEC to seek an Initial Public Offering listing on Nasdaq, with Baird running the deal.
- Evelo Biosciences listed its stock on the Nasdaq exchange on August 1, 2026.
- IPO filings are subject to SEC oversight, involving the Nasdaq stock exchange and the SEC.